JAM
RVLP

JW Asset Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

JW Asset Management’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-225,000
Closed -$864K – 11
2019
Q3 		$864K Hold
225,000
– – 0.76% 8
2019
Q2 		$855K Hold
225,000
– – 0.46% 11
2019
Q1 		$810K Hold
225,000
– – 0.42% 13
2018
Q4 		$1.74M Buy
+225,000
New +$1.8M 1.28% 13

Other funds holding RVLP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JW Asset Management's RVLP Position: Q4 2019 in Review

JW Asset Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2019, closing a stake of 225,000 shares — an estimated $864K sold.

JW Asset Management first reported a position in RVLP in Q4 2018 and held it in 4 quarters. The position peaked at $1.74M in Q4 2018. 50 funds tracked by Wall St. Rank hold RVLP as of Q4 2019.

  • JW Asset Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2019 after selling out during the quarter.
  • JW Asset Management sold 225,000 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2019, an estimated $864K.
  • JW Asset Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 4 quarters.
  • JW Asset Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $1.74M in Q4 2018.
  • 50 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2019.

Based on JW Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.